SCHEMBL6982349

SCHEMBL6982349

CC1=CC(=O)CC(c2ccc(Cl)cc2)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 5/20 0.45
ALOX12 P18054 2/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 4/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPK1 P28482 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6979945 0.83 BRD4 (0.45) POLBLMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL6985384 0.83 BACE1 (0.40) POLBLMNAMAPK1CYP1A2CYP3A4
SCHEMBL6981391 0.81 MAPT (0.43) LMNAALDH1A1HTTMAPTKMT2A
SCHEMBL6985757 0.81 MAPT (0.43) LMNAALDH1A1HTTMAPTKMT2A
SCHEMBL6978662 0.81 MAPT (0.43) LMNAALDH1A1HTTMAPTKMT2A
SCHEMBL15121851 0.76 ALDH1A1 (0.45) POLBLMNAALDH1A1ALOX12HTT
SCHEMBL8442229 0.76 SLC6A3 (0.43) POLBLMNAALDH1A1ALOX12HTT
SCHEMBL1703162 0.75 ABCC1 (0.49) LMNAALDH1A1ALOX12HTTSMN1; SMN2
SCHEMBL1703036 0.75 HPGD (0.45) POLBLMNAALDH1A1ALOX12HTT
SCHEMBL6981637 0.74 POLB (0.58) POLBLMNAALDH1A1ALOX12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1145612-C New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them 2004-04-14 CN disclosed
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed
EP-1050530-A1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers ADIR ET COMPAGNIE (FR) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 POLB 2282/4885LMNA 4702/4885ALDH1A1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.